Immunovaccine Names Joseph Sullivan, Experienced Global Pharmaceutical and Vaccine Executive, as Senior Vice President, Busin...
January 18 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that it has appointed
Joseph Sullivan to the newly created role of Senior Vice President,
Business Development, effective January 22, 2018. Mr. Sullivan
brings over 25 years of global pharmaceutical and vaccine
experience with Merck & Co, Inc. to his new position at
Immunovaccine. His experience includes launching two blockbuster
products, licensing new indications, growing business franchises,
and forming external collaborations to expand market access.
At Immunovaccine, he will be responsible for providing strategic
and operational leadership for the Company’s business development
efforts. This includes expanding late stage candidate development
and preparation for commercialization, as well as forging strategic
commercial partnerships to support further advancement of the
Company’s clinical assets and platform.
“Joe is a seasoned corporate development leader in the
pharmaceutical and vaccine industry,” said Frederic Ors,
Immunovaccine’s Chief Executive Officer. “His experience,
relationships, and reputation for strategic and operational
excellence will be crucial as we move into a pivotal year for
Immunovaccine. We look forward to his contributions in establishing
strategic partnerships with other industry leaders as we bring our
clinical lead asset towards late stage development.”
Mr. Sullivan’s pharmaceutical career has focused on leading
product teams and external collaborations, identifying novel
vaccine targets and technologies for development, and
operationalizing global launch and commercialization plans. Most
recently, he served as the Executive Director, Partner Strategy and
Implementation Lead, at Merck & Co Inc. Prior to holding that
position, he led the New Vaccines Product Group responsible for
commercial direction of new vaccine development. His breadth of
commercial experience includes leading the introduction of
Gardasil® in the US, which achieved over $1 billion of revenue in
the first year, and the expansion of Singulair® into the
respiratory markets.i
“The vaccine and immunotherapy space is very dynamic and
continues to rapidly advance to address unmet medical needs.
Immunovaccine’s product research and clinical development
achievements thus far, including the DepoVax technology, may offer
healthcare providers much-needed new options for their patients’
care,” said Mr. Sullivan. “I am excited to be part of this team and
intend to leverage my broad experience with industry and major
stakeholders to help accelerate the growth and realize the
potential of this Company and its programs.”
Mr. Sullivan has an M.B.A. from Cornell University, and B.A.
from Hamilton College. Prior to graduate school, he was an
Associate in Venture Capital & Investment Banking with Allen
& Company Inc., and completed the financial management training
program at GE Company.
About ImmunovaccineImmunovaccine Inc. is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and infectious diseases.
Immunovaccine develops T cell activating cancer immunotherapies and
infectious disease vaccines based on DepoVax™, the Company’s
patented platform that provides controlled and prolonged exposure
of antigens and adjuvant to the immune system. Immunovaccine has
advanced two T cell activation therapies for cancer through Phase 1
human clinical trials and is currently conducting a Phase 1b study
with Incyte Corporation assessing lead cancer therapy,
DPX-Survivac, as a combination therapy in ovarian cancer. The
Company is also exploring additional applications of DepoVax™,
including DPX-RSV, an innovative vaccine candidate for respiratory
syncytial virus (RSV), which has recently completed a Phase 1
clinical trial. Immunovaccine also has ongoing clinical projects to
assess the potential of DepoVax™ to address malaria and the Zika
virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819
E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
i Gardasil® and Singulair® are registered trademarks of Merck
& Co., Inc.
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024